Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
Status:
Completed
Trial end date:
2014-09-29
Target enrollment:
Participant gender:
Summary
Male and female participants were selected based on chronic neuromuscular pain. Patients were
instructed to take two doses of the placebo or cuprous nicotinic acid chelate Cunermusmir
twice a day for 28 days. Hypothesis: Cunermuspir would improve quality of life as determined
by several questionnaires.